Glyburide

USDailyMed:Glyburide AU:C A10BB01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide 10238-21-8Y 3488 2414 DB01016Y 3368Y SX6K58TVWC D00336Y CHEBI:5441Y ChEMBL472Y DTXSID0037237 Interactive image O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(cc2)CCNC(=O)c3cc(Cl)ccc3OC InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)YKey:ZNNLBTZKUZBEKO-UHFFFAOYSA-NY Glibenclamide, also known asglyburide(U.S.‍‍‍‍‍‍​​​‍​​​​​​ English), is anantidiabetic medicationused to treattype 2 diabetes.It is recommended that it be taken together with diet and exercise.It may be used with otherantidiabetic medication.It is not recommended for use by itself intype 1 diabetes.It is takenby mouth. Common side effects include nausea and heartburn.Serious side effects may includeangioedemaandlow blood sugar.It is generally not recommended duringpregnancybut can be used duringbreastfeeding.It is in thesulfonylureasclass of medications and works by increasing the release ofinsulinfrom thepancreas. Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984.It is available as ageneric medication.In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2million prescriptions.